Funding for this research was provided by:
National Cancer Institute (R01 CA203891, R01 CA121113)
Cancer Research Institute (#)
Stand Up To Cancer (SU2C-AACR-DT1012)
Commonwealth Foundation (#)
Received: 14 September 2018
Accepted: 20 December 2018
First Online: 11 February 2019
Change Date: 6 March 2019
Change Type: Correction
Change Details: .
Ethics approval and consent to participate
: The patients described in this study provided written informed consent as approved by the IRB of Johns Hopkins.
: Not applicable.
: K.N.S., F.H., D.M.P, V.A., B.V., K.W.K., N.P., L.A.D, and V.E.V. have filed for patent protection on a subset of the technologies described herein (US provisional application no. 62/407,820). D.M.P. has ownership interest (including patents) in BMS, MedImmune/AstraZeneca, and Potenza, and is a consultant/advisory board member for BMS and MedImmune/AstraZeneca. V.E.V. has ownership interest (including patents) in Personal Genome Diagnostics and is a consultant/advisory board member for the same.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.